The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.

di Canney, P. A., Dowsett, M., Priestman, T. J.
Pubblicazione 1988

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

di Canney, P. A., Moore, M., Wilkinson, P. M., James, R. D.
Pubblicazione 1984

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.

di Canney, P. A., Wilkinson, P. M., James, R. D., Moore, M.
Pubblicazione 1985

Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

di Jodrell, D. I., Murray, L. S., Reed, N. S., Canney, P. A., Kaye, S. B., Cassidy, J.
Pubblicazione 1994

Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.

di Bissett, D., Jodrell, D., Harnett, A. N., Habeshaw, T., Kaye, S. B., Evans, D., Williams, M., Canney, P. A.
Pubblicazione 1995

Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

di Murri, A M Al, Bartlett, J M S, Canney, P A, Doughty, J C, Wilson, C, McMillan, D C
Pubblicazione 2006

A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.

di Dhokia, B., Canney, P. A., Pectasides, D., Munro, A. J., Moore, M., Wilkinson, P. M., Self, C., Epenetos, A. A.
Pubblicazione 1986

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

di Awada, A, Albanell, J, Canney, P A, Dirix, L Y, Gil, T, Cardoso, F, Gascon, P, Piccart, M J, Baselga, J
Pubblicazione 2008

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer.

di Twelves, C. J., Dobbs, N. A., Curnow, A., Coleman, R. E., Stewart, A. L., Tyrrell, C. J., Canney, P., Rubens, R. D.
Pubblicazione 1994

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

di Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., Canney, P., Fernandez-Salguero, P., Gonzalez, F. J., Cassidy, J., McLeod, H. L.
Pubblicazione 1998

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

di Jones, A L, Barlow, M, Barrett-Lee, P J, Canney, P A, Gilmour, I M, Robb, S D, Plummer, C J, Wardley, A M, Verrill, M W
Pubblicazione 2009

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

di Mackean, M. J., Cassidy, J., Jodrell, D. I., Paul, J., Reed, N. S., Canney, P. A., Yosef, H., Habeshaw, T., Robertson, A. G., McInnes, A., Twelves, C. J.
Pubblicazione 1998

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk bre...

di Thomas, J. S., Hanby, A. M., Russell, N., van Tienhoven, G., Riddle, K., Anderson, N., Cameron, D. A., Bartlett, J. M. S., Piper, T., Cunningham, C., Canney, P., Kunkler, I. H.
Pubblicato in Breast Cancer Res Treat (2017)